| A first-in-class polymerase theta inhibitor selectively targets homologous-recombination-deficient tumors J Zhou, C Gelot, C Pantelidou, A Li, H Yücel, RE Davis, A Färkkilä, ... Nature cancer 2 (6), 598-610, 2021 | 207 | 2021 |
| The NEIL glycosylases remove oxidized guanine lesions from telomeric and promoter quadruplex DNA structures J Zhou, AM Fleming, AM Averill, CJ Burrows, SS Wallace Nucleic acids research 43 (8), 4039-4054, 2015 | 160 | 2015 |
| A role for the fifth G-track in G-quadruplex forming oncogene promoter sequences during oxidative stress: Do these “spare tires” have an evolved function? AM Fleming, J Zhou, SS Wallace, CJ Burrows ACS central science 1 (5), 226-233, 2015 | 136 | 2015 |
| Neil3 and NEIL1 DNA glycosylases remove oxidative damages from quadruplex DNA and exhibit preferences for lesions in the telomeric sequence context J Zhou, M Liu, AM Fleming, CJ Burrows, SS Wallace Journal of Biological Chemistry 288 (38), 27263-27272, 2013 | 129 | 2013 |
| NEIL3 repairs telomere damage during S phase to secure chromosome segregation at mitosis J Zhou, J Chan, M Lambelé, T Yusufzai, J Stumpff, PL Opresko, M Thali, ... Cell reports 20 (9), 2044-2056, 2017 | 79 | 2017 |
| Deficiency of base excision repair enzyme NEIL3 drives increased predisposition to autoimmunity MJ Massaad, J Zhou, D Tsuchimoto, J Chou, H Jabara, E Janssen, ... The Journal of Clinical Investigation 126 (11), 4219-4236, 2016 | 76 | 2016 |
| Inhibiting the oncogenic translation program is an effective therapeutic strategy in multiple myeloma S Manier, D Huynh, YJ Shen, J Zhou, T Yusufzai, KZ Salem, RY Ebright, ... Science translational medicine 9 (389), eaal2668, 2017 | 68 | 2017 |
| Cooperation of the NEIL3 and Fanconi anemia/BRCA pathways in interstrand crosslink repair N Li, J Wang, SS Wallace, J Chen, J Zhou, AD D’Andrea Nucleic Acids Research 48 (6), 3014-3028, 2020 | 66 | 2020 |
| Human CHD1 is required for early DNA-damage signaling and is uniquely regulated by its N terminus J Zhou, J Li, RB Serafim, S Ketchum, CG Ferreira, JC Liu, KA Coe, ... Nucleic acids research 46 (8), 3891-3905, 2018 | 41 | 2018 |
| Heterogeneity and Clonal Evolution of Acquired PARP Inhibitor Resistance in TP53- and BRCA1-Deficient Cells A Färkkilä, A Rodríguez, J Oikkonen, DC Gulhan, H Nguyen, ... Cancer research 81 (10), 2774-2787, 2021 | 20 | 2021 |
| Targeting DNA Repair with Combined Inhibition of NHEJ and MMEJ Induces Synthetic Lethality in TP53-Mutant Cancers J Patterson-Fortin, A Bose, WC Tsai, C Grochala, H Nguyen, J Zhou, ... Cancer research 82 (20), 3815-3829, 2022 | 16 | 2022 |
| In Vitro Adsorption Revealing an Apparent Strong Interaction Between Endophyte Pantoea agglomerans YS19 and Host Rice Y Miao, J Zhou, C Chen, D Shen, W Song, Y Feng Current microbiology 57, 547-551, 2008 | 16 | 2008 |
| SPM43.1 Contributes to Acid-Resistance of Non-Symplasmata-Forming Cells in Pantoea agglomerans YS19 Q Li, Y Miao, T Yi, J Zhou, Z Lu, Y Feng Current microbiology 64, 214-221, 2012 | 11 | 2012 |
| Novobiocin blocks nucleic acid binding to Polθ and inhibits stimulation of its ATPase activity A Syed, F Filandr, J Patterson-Fortin, A Bacolla, R Ravindranathan, ... Nucleic acids research 51 (18), 9920-9937, 2023 | 5 | 2023 |
| Increased frequency of CHD1 deletions in prostate cancers of African American men is associated with distinct homologous recombination deficiency associated DNA aberration profiles M Diossy, V Tisza, H Li, J Zhou, Z Sztupinszki, D Young, D Nousome, ... medRxiv, 2021.02. 08.21251199, 2021 | 3 | 2021 |
| Novobiocin blocks nucleic acid binding to Pol and inhibits stimulation of its ATPase activity A Syed, F Filandr, J Patterson-Fortin, A Bacolla, R Ravindranathan, ... Nucleic Acids Research, 1, 2023 | | 2023 |
| Dual inhibition of NHEJ and MMEJ induces synthetic lethality in TP53 mutant cancers J Patterson-Fortin, A Bose, WC Tsai, C Grochala, H Nguyen, J Zhou, ... Cancer Research 82 (12_Supplement), 796-796, 2022 | | 2022 |
| TRIP13 amplification confers PARP inhibitor resistance and polymerase theta inhibitor sensitivity J Patterson-Fortin, J Zhou, A D'Andrea Cancer Research 81 (13_Supplement), 2052-2052, 2021 | | 2021 |
| Abstract NT-092: FUNCTIONAL HETEROGENEITY OF ACQUIRED PARP INHIBITOR RESISTANCE IN BRCA1-DEFICIENT CELLS A Färkkilä, A Rodriquez, J Olkkonen, L Sambel, N Joshi, C Clairmont, ... Clinical Cancer Research 25 (22_Supplement), NT-092-NT-092, 2019 | | 2019 |
| FUNCTIONAL HETEROGENEITY OF ACQUIRED PARP INHIBITOR RESISTANCE IN BRCA1-DEFICIENT CELLS A Farkkila, A Rodriquez, J Olkkonen, L Sambel, N Joshi, C Clairmont, ... CLINICAL CANCER RESEARCH 25 (22), 204-204, 2019 | | 2019 |
Cynthia BurrowsProfessor of Chemistry, University of UtahVerified email at chem.utah.edu
